Hold off investments: company postponing future planned investment/development/marketing while continuing substantive business
Stay Pausing Investments
Polpharma SA is a Polish pharmaceutical company that produces medicines for cardiology, gastroenterology and neurology. Polpharma is among the 20 largest generics companies in the world, with a turnover of approx. 1 billion dollars a year. It employs more than 7,500 people in Poland and in some foreign markets. The company has 7 production plants in Poland, Russia and Kazakhstan, and 7 centers of research and development.
Hold off investments: company postponing future planned investment/development/marketing while continuing substantive business
Stay Pausing InvestmentsThe company for the Russian market currently includes only pediatric products, products used in emergency cases or in the treatment of chronic diseases. This product is important for health, so its deliveries to Russia will continue. However, the company abandoned products that have a vital nature and only improve the quality of life.
March 28, 2022: Polpharma have decided to stop all new investments in Russia. Shipments to Russia only include essential drugs. Prior to March 28, sold pediatric products and products used for treatment of acute or chornic medical conditions. Donating medications to Ukraine. Does not import any medicines, active ingredients, or raw materials for production from Russia or Belarus. (Akrikhin, a Russian pharmaceutical company, is listed as an asset. Poland's largest drug maker).
| March 19, 2022 | Statement of ZF POLPHARMA S.A. |